Evidence map›Paper›PMID 25584796›Full record

ArticleDevelopmental cell2015

The endothelial transcription factor ERG promotes vascular stability and growth through Wnt/β-catenin signaling.

Graeme M Birdsey, Aarti V Shah, Neil Dufton, Louise E Reynolds, Lourdes Osuna Almagro, Youwen Yang, Irene M Aspalter, Samia T Khan, Justin C Mason, Elisabetta Dejana and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Developmental cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 171 papers.

0numbers the graph read from it
0cells of the map it votes in
171citing papers in PubMed
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

171 citing papers in PubMed, 265 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016
    Trial
  4. Molecular Mechanisms Governing Vascular Function in Heart Failure.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

111 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Graeme M BirdseyNational Heart and Lung Institute (NHLI) Vascular Sciences, Hammersmith Hospital, Imperial College London, London W12 0NN, UK.
Aarti V ShahNational Heart and Lung Institute (NHLI) Vascular Sciences, Hammersmith Hospital, Imperial College London, London W12 0NN, UK.
Neil DuftonNational Heart and Lung Institute (NHLI) Vascular Sciences, Hammersmith Hospital, Imperial College London, London W12 0NN, UK.
Louise E ReynoldsCentre for Tumour Biology, Barts Cancer Institute - a CR-UK Centre of Excellence, John Vane Science Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Lourdes Osuna AlmagroNational Heart and Lung Institute (NHLI) Vascular Sciences, Hammersmith Hospital, Imperial College London, London W12 0NN, UK.
Youwen YangNational Heart and Lung Institute (NHLI) Vascular Sciences, Hammersmith Hospital, Imperial College London, London W12 0NN, UK.
Irene M AspalterVascular Biology Laboratory, London Research Institute, Cancer Research UK, London WC2A 3PX, UK.
Samia T KhanNational Heart and Lung Institute (NHLI) Vascular Sciences, Hammersmith Hospital, Imperial College London, London W12 0NN, UK.
Justin C MasonNational Heart and Lung Institute (NHLI) Vascular Sciences, Hammersmith Hospital, Imperial College London, London W12 0NN, UK.
Elisabetta DejanaFIRC Institute of Molecular Oncology Foundation, IFOM, 20139 Milan, Italy.
Berthold GöttgensDepartment of Haematology, Wellcome Trust and MRC Cambridge Stem Cell Institute and Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, UK.
Kairbaan Hodivala-DilkeCentre for Tumour Biology, Barts Cancer Institute - a CR-UK Centre of Excellence, John Vane Science Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Holger GerhardtVascular Biology Laboratory, London Research Institute, Cancer Research UK, London WC2A 3PX, UK.
Ralf H AdamsDepartment of Tissue Morphogenesis, Max Planck Institute for Molecular Biomedicine and Faculty of Medicine, University of Münster, D-48149 Münster, Germany.
Anna M RandiNational Heart and Lung Institute (NHLI) Vascular Sciences, Hammersmith Hospital, Imperial College London, London W12 0NN, UK. Electronic address: a.randi@imperial.ac.uk.
Imperial College London · GBCancer Research UK · GBFIRC Institute of Molecular Oncology · ITHammersmith Hospital · GBMax Planck Institute for Molecular Biomedicine · DEUniversity of Cambridge · GB

Funding

British Heart Foundation PG/09/096British Heart Foundation PG/09/096/28114British Heart Foundation PG/10/94/28651British Heart Foundation RG/11/17/29256Cancer Research UK 12007Cancer Research UK 12765Cancer Research UK 18673Medical Research Council G0901609Medical Research Council MC_PC_12009Wellcome Trust 97922Worldwide Cancer Research 12-1068
6 · The paper itself

Abstract

Blood vessel stability is essential for embryonic development; in the adult, many diseases are associated with loss of vascular integrity. The ETS transcription factor ERG drives expression of VE-cadherin and controls junctional integrity. We show that constitutive endothelial deletion of ERG (Erg(cEC-KO)) in mice causes embryonic lethality with vascular defects. Inducible endothelial deletion of ERG (Erg(iEC-KO)) results in defective physiological and pathological angiogenesis in the postnatal retina and tumors, with decreased vascular stability. ERG controls the Wnt/β-catenin pathway by promoting β-catenin stability, through signals mediated by VE-cadherin and the Wnt receptor Frizzled-4. Wnt signaling is decreased in ERG-deficient endothelial cells; activation of Wnt signaling with lithium chloride, which stabilizes β-catenin levels, corrects vascular defects in Erg(cEC-KO) embryos. Finally, overexpression of ERG in vivo reduces permeability and increases stability of VEGF-induced blood vessels. These data demonstrate that ERG is an essential regulator of angiogenesis and vascular stability through Wnt signaling.

Indexed as

Neovascularization, PhysiologicAnimalsAntigens, CDbeta CateninBlotting, WesternCadherin 5CadherinsCells, CulturedChromatin ImmunoprecipitationEndothelium, VascularFemaleFrizzled ReceptorsHumansHuman Umbilical Vein Endothelial CellsIntegrasesLungAntigens, CDbeta CateninCadherin 5CadherinsCre recombinaseERG protein, mouseFrizzled ReceptorsFzd4 protein, mouseIntegrasesOncogene ProteinsTranscriptional Regulator ERGTranscription FactorsVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouseWnt Proteins

Identifiers

PMID25584796
PMCPMC4292982
OpenAlexW2013410789

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.